SGLT2 inhibitor dapagliflozin enhances skeletal muscle fatty acid uptake in subjects with type 2 diabetes: a positron emission tomography study

被引：0
|
作者：
Latva-Rasku, A. [1 ]
Tuisku, J. [1 ]
Bhowmik, A. [1 ]
Keskinen, H. [1 ]
Rebelos, E. [1 ]
Laurila, S. [1 ]
Koffert, J. [1 ]
Nummenmaa, L. [1 ]
Heurling, K. [2 ]
Oscarsson, J. [3 ]
Turku, P. Nuutila [1 ]
机构：
[1] Univ Turku, Turku PET Ctr, Turku, Finland
[2] Antaros Med, Molndal, Sweden
[3] AstraZeneca AB, Molndal, Sweden
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [21] Effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes
    Op den Kamp, Y.
    de Ligt, M.
    Dautzenberg, B. D.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Havekes, B.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S115 - S115
  • [22] Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin
    Jabbour, Serge A.
    Whaley, Jean M.
    Tirmenstein, Mark
    Poucher, Simon M.
    Reilly, Timothy P.
    Boulton, David W.
    Saye, JoAnne
    List, James F.
    Parikh, Shamik
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 62 - 73
  • [23] Dapagliflozin, a selective SGLT2 inhibitor, has a low propensity to cause hypoglycaemia in patients with type 2 diabetes
    Rohwedder, K.
    Hrub, V.
    Salsali, A.
    Ying, L.
    Sugg, J.
    List, J. F.
    Parikh, S.
    DIABETOLOGIA, 2011, 54 : S348 - S349
  • [24] Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes
    Voigt, Jens Hohwu
    Lauritsen, Katrine M.
    Pedersen, Steen Bonlokke
    Hansen, Troels K.
    Moller, Niels
    Jessen, Niels
    Laurenti, Marcello C.
    Dalla Man, Chiara
    Vella, Adrian
    Gormsen, Lars C.
    Sondergaard, Esben
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 134 (05) : 643 - 656
  • [25] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Paola Fioretto
    Andrea Giaccari
    Giorgio Sesti
    Cardiovascular Diabetology, 14
  • [26] Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
    Fioretto, Paola
    Giaccari, Andrea
    Sesti, Giorgio
    CARDIOVASCULAR DIABETOLOGY, 2015, 14
  • [27] THE RENOPROTECTIVE EFFECT OF SODIUM-GLUCOSE COTRANSPORTER2 (SGLT2) INHIBITOR DAPAGLIFLOZIN IN TYPE 1 DIABETES
    Hodrea, Judit
    Lenart, Lilla
    Koszegi, Sandor
    Gellai, Renata
    Balogh, Dora B.
    Vannay, Adam
    Wagner, Laszlo J.
    Szabo, Attila J.
    Fekete, Andrea
    PEDIATRIC NEPHROLOGY, 2015, 30 (09) : 1633 - 1634
  • [28] Exposure-efficacy outcome modeling for dapagliflozin, an orally selective SGLT2 inhibitor, in patients with type 2 diabetes
    Feng, Yan
    Zhang, Liping
    List, James F.
    Pfister, Marc
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1114 - 1114
  • [29] Treatment with SGLT2 inhibitor dapagliflozin for non-alcoholic steatohepatitis patients complicated with type 2 diabetes mellitus
    Tobita, Hiroshi
    Sato, Shuiti
    Miyake, Tatuya
    Yazaki, Tomotaka
    Isoda, Kazuki
    Mishiro, Tuyoshi
    Ishihara, Shunji
    Kinoshita, Yoshikazu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 388 - 388
  • [30] Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects
    Wilmsen, HM
    Ciaraldi, TP
    Carter, L
    Reehman, N
    Mudaliar, SR
    Henry, RR
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (02): : E354 - E362
12345